Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia‐1

• DOI: 10.1002/hed.24096
• Publication Date: 2015-04-27T10:02:00Z
• Authors: Haeng‐Eun Lee; Jeong‐Seok Nam; Ji‐Ae Shin; In‐Sun Hong; In‐Hyoung Yang; Myung‐Jo You; Sung‐Dae Cho
• Keywords: 0301 basic medicine; Caspase 3; Plant Extracts; Apoptosis; Salivary Gland Neoplasms; Convallaria; 3. Good health; 03 medical and health sciences; Proto-Oncogene Proteins c-bcl-2; Cell Line, Tumor; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Molecular Targeted Therapy; RNA, Small Interfering; Phytotherapy

Various chemotherapeutic agents have been used largely for the treatment of salivary gland cancer. However, results are disappointing, and these can cause some serious side effects. Therefore, recent studies focused on possible roles natural products to overcome limitations.Salivary cancer cells treated with or without Convallaria keiskei (MECK) 24 hours. Apoptotic changes were evaluated by live/dead assay, immunoblotting, expression levels caspase-3 B-cell lymphoma-2 family member.MECK significantly inhibited growth. At molecular level, MECK dramatically reduced myeloid cell leukemia-1 (Mcl-1) in a translation-dependent manner thereby induced apoptosis through Bax/Bid. Furthermore, we found that Mcl-1 could be potential therapeutic target MECK-induced its stability is regulated extracellular signal-regulated kinases 1/2 (ERK1/2) signalingMECK as safe efficient alternative © 2015 Wiley Periodicals, Inc. Head Neck 38: E761-E770, 2016.